Time to treatment initiation increasing for patients with head and neck cancer

This article originally appeared here.
Time to Treatment Increasing With Head, Neck Cancer
Time to Treatment Increasing With Head, Neck Cancer

(HealthDay News) -- Time to treatment initiation (TTI) is rising for patients with head and neck squamous cell carcinoma, according to a study published online Dec. 9 in Cancer.

Colin T. Murphy, M.D., from the Fox Chase Cancer Center in Philadelphia, and colleagues analyzed data from the National Cancer Database to identify head and neck cancer sites (oral tongue, oropharynx, larynx, and hypopharynx) and to determine TTI (the number of days from diagnosis to the initiation of definitive treatment).

The researchers found that based on 274,630 patients from 1998 to 2011, the median TTI for all patients was 26 days, and increased from 19 to 30 days (P < 0.0001). Increased TTI was associated with treatment with chemoradiation (CRT; P < 0.0001), treatment at an academic facility (P < 0.0001), and stage IV disease (P < 0.0001). For each disease stage (P < 0.0001), treatment modality (P < 0.0001), and facility type (P < 0.0001), TTI significantly increased over time. Longer TTI was predicted in multivariate analysis by treatment at an academic facility (33 days), transitioning care (37 days), and receipt of CRT (39 days).

"Those who have advanced-stage disease, receive treatment with CRT, are treated at academic facilities, and who have a transition in care realized the greatest increases in TTI," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text (subscription or payment may be required)

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs